The fecal pancreatic Elastase ELISA from BIOSERV Diagnostics has been registered with the FDA
For the diagnosis of a pancreatic insufficiency
In-vitro test kit for the quantitative detection of human fecal pancreatic elastase in stool in order to diagnose and quantify pancreatic insufficiency.
Advantages of determining fecal pancreatic elastase:
Fecal pancreatic Elastase is exclusively produced in the pancreas and therefore excellently suitable todiagnose pancreatic malfunctions like pancreatic insufficiency
Fecal pancreatic Elastase is extraordinary stable when passing through the bowels
Pancreatic Elastase is enriched 5-6 fold in feces in comparison to the concentration in the duodenal juice
Fecal pancreatic Elastase has a small intra-personal variation in regarding the concentration
Direct correlation of fecal pancreatic Elastase concentration and pancreatic function
no age-dependency of the fecal pancreatic elastase secretion from infancy (first year) on
the fecal pancreatic elastase molecule is stable for at least 6 days at refrigeration and for at least 3 days at room temperature
FDA-registered
The Bioserv Elastase ELISA for the detection of fecal pancreatic Elastaseallows a highly sensitive and specific determination of fecal pancreatic Elastase, enabling the clinician to establish a prompt and reliable diagnosis of suspected cases of pancreatic insufficiency.